|1.||Schulman, S: 1 article (03/2003)|
|2.||Schindel, F: 1 article (03/2003)|
|3.||Stabler, S: 1 article (03/2003)|
|4.||Schwartz, B A: 1 article (03/2003)|
|5.||Negrier, C: 1 article (03/2003)|
|6.||Hoots, W K: 1 article (03/2003)|
|7.||Leissinger, C: 1 article (03/2003)|
|8.||Massion, C: 1 article (03/2003)|
|9.||White, G: 1 article (03/2003)|
|10.||Dasani, H: 1 article (03/2003)|
|1.||Hemophilia B (Haemophilia B)
01/01/1995 - "These studies indicate that Mononine is safe and effective in the treatment of hemorrhagic episodes in patients with hemophilia B."
02/01/1992 - "Mononine was evaluated for in vivo recovery, half-life, and for its safety and efficacy in 10 patients with hemophilia B. "
01/01/1995 - "Pharmacokinetic variables were studied in severe hemophilia B patients: Nanotiv was compared with Preconativ; Immunine was compared with Prothromplex TIM4 in crossover studies; and Mononine was tested in a single-drug study. "
11/15/1993 - "In vivo, Nanotiv was compared with Preconativ and Immunine with Prothromplex TIM4 in crossover studies in patients with severe hemophilia B, and Mononine was tested in a single drug study. "
05/01/1995 - "Monoclonal antibody purified factor IX concentrate, Mononine (Armour Pharmaceutical Company, Kankakee, Illinois, USA), is a recently developed replacement factor concentrate for the treatment of patients with hemophilia B. "
|2.||prothrombin complex concentrates (PPSB)
|3.||Factor IX (PTC)
|4.||6-Aminocaproic Acid (6 Aminocaproic Acid)
|5.||Tranexamic Acid (AMCA)
|6.||Antifibrinolytic Agents (Antifibrinolytics)